Hemostasis in women with obesity and metabolic syndrome

• Published in: РМЖ: Медицинское обозрение Vol. 5; no. 9; pp. 598 - 604
• Main Authors: Kuzina, I.A., Goncharova, E.V., Martirosyan, N.S., Telnova, M.E., Atamanova, Yu.A., Yudina, K.A., Petunina, N.A.
• Format: Journal Article
• Language: English
• Published: 2021
• ISSN: 2587-6821; 2686-9918
• DOI: 10.32364/2587-6821-2021-5-9-598-604

To date, obesity is a global epidemic that resulted in increased morbidity and mortality, including those associated with thrombotic conditions. Metabolic syndrome (MS) is characterized by abdominal obesity, glucose metabolism disorders, hypertension, and dyslipidemia. Patients with MS have higher risks of thrombosis and cardiovascular events. Hemostatic disorders in women with obesity and MS are an important clinical issue. Hemostatic abnormalities in these patients (hypercoagulation, hypofibrinolysis, platelet dysfunctions) increase the risk of cardiovascular morbidity and mortality and venous thromboembolism (VTE). Combined oral contraceptives (COCs) increase VTE risk in women with obesity. During pregnancy and postnatal period, obesity is one of the most common causes of VTE. In postmenopause, obesity and MS, and COCs prescribed as menopausal hormone therapy require close attention in controlling hemostatic parameters. This paper reviews significant hemostatic abnormalities in obesity and MS and discusses the role of these conditions in developing hemostatic disorders and VTE in women of reproductive age and postmenopause. KEYWORDS: obesity, metabolic syndrome, hemostasis, combined oral contraceptives, pregnancy, postmenopause, venous thromboembolism. FOR CITATION: Kuzina I.A., Goncharova E.V., Martirosyan N.S. et al. Hemostasis in women with obesity and metabolic syndrome. Russian Medical Inquiry. 2021;5(9):598–604 (in Russ.). DOI: 10.32364/2587-6821-2021-5-9-598-604.